Are we supposed to be surprised by the 8-K Baudax filed this morning?
More importantly, are Durrant, Dale, and TeraImmune's co-founder, Jay Park, surprised?
These are the steps taken to date.
Jay Park accepts a deal to transfer all equity interest of TeraImmune to Baudax in a stock-for-stock acquisition on June 30th, 2023, the last day of Q2.
So are Dale, Durrant, and Jay Park SHOCKED by this 8-K?
My opinion is not worth more than yours. But for what it is worth, I see this last step as just a continuation of our carefully-contrived strategy. I hope that this strategy culminates with more fully leveraging our investment in Baudax, and in announcing that we are accepting a stock-for-stock merger agreement, perhaps with Novavax.
But however it turns out, I don't think any of the players are bemoaning the unexpected loss of their equity or investment dollars in less than two quarters from the time they entered into these deals.